clinical trial · NCT04046549
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Amgen·phase2·completed·n = 25
AllograftsRejection; Transplant, KidneyTransplant RejectionKidney TransplantationBelataceptVIB4920ThymoglobulinMethylprednisolone
brief summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.
started
Oct 30, 2019
primary completion
Jul 18, 2022
completion
Mar 22, 2023
last updated
Dec 27, 2024
detailed description
Study with completed results acquired from Horizon in 2024.
official title
A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol